Pancreatic Cancer Drug
-
{
- All
- News
-
New Landmark Drug Nearly Doubles Survival In Advanced Pancreatic Cancer, FDA Approves
The US FDA has approved daraxonrasib, a targeted oral drug for previously treated metastatic pancreatic cancer. In a 500-patient trial, it nearly doubled median overall survival compared with standard chemotherapy
-
Exclusive: Biggest Pancreatic Cancer Breakthrough In 50 Years, Says Indian Doctor, Co-Author Of Global Clinical Trial
Daraxonrasib belongs to a new class of medicines known as RAS(ON) inhibitors. The drug targets the active form of RAS proteins, which help drive tumour growth and survival.
-
New Landmark Drug Nearly Doubles Survival In Advanced Pancreatic Cancer, FDA Approves
The US FDA has approved daraxonrasib, a targeted oral drug for previously treated metastatic pancreatic cancer. In a 500-patient trial, it nearly doubled median overall survival compared with standard chemotherapy
-
Exclusive: Biggest Pancreatic Cancer Breakthrough In 50 Years, Says Indian Doctor, Co-Author Of Global Clinical Trial
Daraxonrasib belongs to a new class of medicines known as RAS(ON) inhibitors. The drug targets the active form of RAS proteins, which help drive tumour growth and survival.
